Roche says studies show its drugs help breast cancer
Key points
- New data shows that three drugs made by Roche Holding AG help patients with breast cancer live longer or remain disease-free for longer, the Swiss drugmaker said Wednesday.
- Roche, the world's largest maker of cancer drugs, is presenting new data at the San Antonio Breast Cancer Symposium which show that its Herceptin (trastuzumab), Xeloda (capecitabine) and Avastin (bevacizumab) drugs can help patients with early or advanced breast cancer live longer.
- Roche said it would present data from a phase III study that showed that women with locally advanced breast cancer had a significantly greater chance of living disease-free 3years after treatment if they took Herceptin prior to surgery along with standard chemotherapy.
- An independent study in Finland and Sweden indicates that chemotherapy pill Xeloda, already proven in advanced breast cancer, might also reduce the recurrence of early breast cancer, the company said.
New data shows that three drugs made by Roche Holding AG help patients with breast cancer live longer or remain disease-free for longer, the Swiss drugmaker said Wednesday.
Roche, the world's largest maker of cancer drugs, is presenting new data at the San Antonio Breast Cancer Symposium which show that its Herceptin (trastuzumab), Xeloda (capecitabine) and Avastin (bevacizumab) drugs can help patients with early or advanced breast cancer live longer.
Roche said it would present data from a phase III study that showed that women with locally advanced breast cancer had a significantly greater chance of living disease-free 3years after treatment if they took Herceptin prior to surgery along with standard chemotherapy.
An independent study in Finland and Sweden indicates that chemotherapy pill Xeloda, already proven in advanced breast cancer, might also reduce the recurrence of early breast cancer, the company said.
Roche will also present numerous studies on Avastin, including one from the largest ever safety study in a real-life setting, which shows the drug can give breast cancer patients an average of almost 10 months without their disease getting worse.
Separately, Roche also said it was presenting long-term phase III data at the annual meeting of the American Society of Hematology that confirms the positive impact of its MabThera therapy for patients in remission with recurrent/resistant Non-Hodgkin's lymphoma.
It said the data showed that those receiving MabThera lived almost 2.5 years longer without their disease progressing than those not receiving the treatment.
ZURICH (Reuters)
Written and revised by
David Cohen, M.D.
Our doctors write and review articles for accuracy and keep them up to date.
health.am provides general information, not medical advice. Always consult a qualified health professional about your own health.
Explore health topics
More in this topic
Cancer →
NewsStopping ovarian cancer in its tracks: An antibody may help patients heal themselves
Ovarian cancer is the seventh most common cancer among women worldwide, and it often goes undetected until it has spread to other parts of the body. More than 70% of ovarian cancer patients experience relapse; when…
2 December 2015
NewsResearchers find experimental drug can help fight debilitating side effect of ovarian cancer
Women who have ovarian cancer often develop a condition called ascites, which is a buildup of fluids in the abdomen. The most common treatment for ascites is puncturing the abdomen and manually draining the fluid, which…
18 November 2015
NewsTwo-drug combination shows promise against one type of pancreatic cancer
One form of pancreatic cancer has a new enemy: a two-drug combination discovered by UF Health researchers that inhibits tumors and kills cancer cells in mouse models. For the first time, researchers have shown that a…
